Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Akari Therapeutics ( (AKTX) ).
On March 17, 2026, Akari Therapeutics announced it will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares, effective around March 31, 2026. The move amounts to a one-for-forty reverse split of issued and outstanding ADSs, with no impact on the underlying ordinary shares, and the stock will continue trading on the Nasdaq Capital Market under the symbol AKTX.
The company said the ADS ratio change is intended to help it maintain compliance with Nasdaq’s minimum bid price requirement for continued listing, with Deutsche Bank handling the exchange of old ADSs for new ones and fractional entitlements to ADSs being aggregated, sold, and returned as cash to holders. While Akari expects the ADS price to rise proportionally after the reverse split, it cautioned that there is no assurance the price performance will be sufficient to secure ongoing Nasdaq compliance, an issue closely watched by investors and other stakeholders.
The most recent analyst rating on (AKTX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
The score is pressured primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events are mixed—financing helps liquidity, but the Nasdaq delisting risk is a significant overhang—while valuation inputs are unavailable, limiting conviction from that component.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics, Plc is an oncology-focused biotechnology company developing next-generation antibody drug conjugates (ADCs) that use a proprietary RNA splice–modulating payload known as PH1. Its lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells, while a second program, AKTX-102, targets the CEACAM5 tumor antigen across multiple solid tumors.
Using its ADC discovery platform, Akari aims to generate and optimize ADCs against a range of antigen targets, seeking more effective and durable cancer treatments with reduced off-target effects. The company has initiated IND-enabling studies for AKTX-101 and is planning a first-in-human trial in late 2026 or early 2027, positioning it in the competitive next-generation oncology therapeutics market.
Average Trading Volume: 665,491
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.75M
See more insights into AKTX stock on TipRanks’ Stock Analysis page.